Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rinzimetostat · 1 trial · 1 indication
Radiographic Progression Free Survival is defined as the time from the date of randomization to first evidence of radiographic progression as assessed in soft tissue by RECIST 1.1 or in bone per PCWG3 guideline by BICR, or death, whichever occurs first
| Arm | Type | Description |
|---|---|---|
| Investigational Arm | ACTIVE_COMPARATOR | Rinzimetostat + darolutamide |
| Physician's Choice | ACTIVE_COMPARATOR | Control Arm |
| Name | Type | Description |
|---|---|---|
| Rinzimetostat | DRUG | 400 mg once daily (QD) |
| Darolutamide | DRUG | 600 mg twice daily (BID) |
| Enzalutamide | DRUG | 160 mg once daily (QD) |
| Docetaxel | DRUG | 75 mg/m2 intravenously (IV) every 21 days for up to 10 cycles |
Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features * Progressive disease in the setting of surgical or medical castration with evidence of disease progression on treatment with abiraterone acetate in the mCSPC setting or first ...
Rinzimetostat is an investigational small molecule being studied for the treatment of metastatic castration resistant prostate cancer (mCRPC). It is currently in Phase 3 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in patients who were previously treated with abiraterone acetate.
Rinzimetostat is a small molecule enzyme inhibitor, as indicated by its '-stat' suffix, which typically denotes enzyme inhibition. The specific molecular target has not been disclosed in available information. The drug is being investigated for its potential role in treating metastatic castration resistant prostate cancer.
Rinzimetostat is being developed by Oric Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol ORIC. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with metastatic castration resistant prostate cancer.
Rinzimetostat is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval for commercial use. The Phase 3 trial is actively recruiting participants to further assess the drug's effectiveness in treating metastatic castration resistant prostate cancer.
Rinzimetostat is being studied in a Phase 3 clinical trial registered as NCT07723248, titled 'A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)'. The trial is actively recruiting 600 male participants aged 18 years and older in the United States.
Yes, Rinzimetostat is also known as ORIC-944. The clinical trial NCT07723248 refers to the drug as 'Rinzimetostat (ORIC-944)', confirming that both names refer to the same investigational compound being developed by Oric Pharmaceuticals for metastatic castration resistant prostate cancer.